Funder profile: TTP Ventures
TTP Ventures based near Cambridge provides investment and support for IT, MedTech and CleanTech companies. It currently manages a £34m fund that has been invested across different technology sectors.
Part of TTP Group, Europe’s leading technology development and licensing company, TTP Ventures gains access to the broad range of experience and contacts of TTP’s engineers and scientists. This helps the VC firm to contribute a high degree of added value to the businesses it supports and invests in.TTP Ventures’ work with the Carbon Trust-TTP Incubator gives the firm great insight into the CleanTech space. The incubator is funded by the Carbon Trust and provides services to accelerate the development of businesses in the low carbon sector. TTP Ventures supplies commercial and financial skills alongside the scientific, engineering and market research capabilities of TTP Group.So far TTP Ventures’ first fund has had four very successful exits - Element 14 ($250m trade-sale), Alphamosaic ($123m trade-sale), Oxford Diffraction ($37m trade-sale) and Argenta Discovery 2009 (€16.5m trade-sale).Founders and management teams of innovative technology companies have selected TTP Ventures as their partners. TTP Ventures believes that its approach to investing is different from other venture firms. It focuses on sectors that it understands well and where it can add value to a business. TTP Ventures likes to invest in electronic devices and semiconductors; clean technologies particularly those in energy efficiency, waste handling and materials usage; instrumentation and related hardware for industrial applications; enablers for mobility, wireless communications and connectivity; medical technologies helping to address unmet healthcare needs. Investments range in size from as little as £250k to as much as £15 million per company (usually as part of a syndicate of investors).
Azuro - www.azuro.comAn electronic design automation company supplying software tools to electronics enterprises.
CamSemi - www.camsemi.comA spin out from Cambridge University and a fabless semiconductor company developing new generations of power ICs.
Pulmagen Therapeutics - www.mvmlifescience.comPulmagen was formed following the acquisition of Argenta Discovery 2009 Limited by Galapagos NV. Ownership of Argenta's respiratory development programs transferred into Pulmagen Therapeutics, a development stage biotechnology company that aims to progress novel therapies to treat chronic respiratory diseases including COPD, severe asthma and cystic fibrosis. These therapies aim to deliver both improved bronchodilator symptomatic relief and treat the underlying inflammatory disease process. Pulmagen intends to progress its programs through Phase IIa proof of concept clinical trials and identify strategic partners for later stage clinical development. The company has partnered respiratory development programs with AstraZeneca, Domantis (GSK) and Dr. Reddy's.
TeraView - www.teraview.comTeraView was spun-out of Toshiba Research Europe in April 2001 by its co-founders, Sir Michael Pepper and current CEO, Dr Don Arnone, to exploit the intellectual property and expertise developed in sourcing and detecting terahertz (THz=1012Hz) radiation, using innovative semiconductor technologies. Leading industry proponents of the technology sit on the firm’s advisory board and TeraView maintains close links with the Cavendish Laboratory at the University of Cambridge, where modern terahertz technology was pioneered in conjunction with the team at TeraView, and where Professor Pepper, has held the position of Professor of Physics since 1987. In March 2011 TeraView was bidding to raise £2 million to exploit a game-changing opportunity in multi-billion dollar mobile phone and tablet personal computer markets identified through an alliance with Intel.